Myriad Genetics Inc (MYGN) - News Archive

Myriad Genetics, Inc. continues to make significant strides in the field of molecular diagnostics and precision medicine, successfully translating cutting-edge research into clinical practice. Recently, a groundbreaking...

: Recent research published in the Journal of Clinical Psychopharmacology has unveiled compelling evidence regarding the efficacy of the GeneSight pharmacogenomic test in optimizing antidepressant response and remission...

Myriad Genetics: Unveiling Clinical Validity of Precise MRD at AACR Annual MeetingIn an era where precision medicine is increasingly guiding therapeutic decisions, Myriad Genetics continues to make impressive strides. T...

In a significant development poised to shape the future trajectory of corporate governance and risk management, Myriad Genetics has announced a transition in its senior leadership. Effective April 30, 2025, Sam Raha wil...

In the rapidly evolving landscape of governance, risk, and compliance (GRC), Diligent continues to position itself as a key player in providing advanced software-as-a-service (SaaS) solutions. Recently highlighted in S&...

Myriad Genetics Unveils Promising Financial Guidance for 2025 Amid Strategic InnovationsIn a recent press release, Myriad Genetics, a leading molecular diagnostic company, showcased its preliminary financial outcomes fo...

In an evolving landscape of prostate cancer diagnostics and treatment, Myriad Genetics Prolaris test stands out as a significant advancement, recently classified as an advanced tool by the National Comprehensive Cancer...

Advancing Genetic Testing: Myriad Genetics’ Strategic Partnerships to Transform Precision Medicine In a significant stride towards enhancing access and equity in genetic testing, Myriad Genetics, Inc. (NASDAQ: MYGN), re...

In a groundbreaking move poised to reshape the landscape of healthcare, Myriad Genetics, a leader in genetic testing and innovative diagnostics, has announced a strategic partnership with Flatiron Health, a frontrunner...

In a pivotal move that could reshape the landscape of genetic testing, Myriad Genetics, a prominent player in precision medicine, has announced a strategic collaboration with Ultima Genomics, a company on the cutting ed...

Myriad Genetics Reshapes Focus with Eurobio Scientific Deal: A Strategic Shift in Precision Medicine In a significant move aimed at bolstering its international presence and focusing on its core genetic testing operatio...

Myriad Genetics, Inc., a renowned leader in genetic testing and precision medicine, has recently unveiled a breakthrough study published in Genetics in Medicine. This study validates RiskScore, an innovative breast canc...

QIAGEN and Myriad Genetics Collaborate to Develop Distributable Homologous Recombination Deficiency Test for Precision Medicine ResearchQIAGEN, a leading provider of molecular diagnostics solutions, and Myriad Genetics,...

Cancer treatment has witnessed significant advancements in recent years, largely owing to diagnostic tools such as molecular residual disease (MRD) testing. MRD testing has revolutionized cancer care by enabling early d...

A remarkable scientific study spearheaded by Myriad Genetics, Inc., a pioneering front-runner in genetic testing and precision medicine, has been recently published in Prenatal Diagnosis. This groundbreaking study illus...

In a remarkable collaboration between Myriad Genetics and the National Cancer Center Hospital East in Japan, the stage is set for a transformative clinical trial: SCRUM-MONSTAR-SCREEN-3. This innovative study aims to re...

In a move aimed at bolstering its position in the field of genetic testing and precision medicine, Myriad Genetics, Inc. (NASDAQ: MYGN) has appointed esteemed physician Dr. Dallas Reed as the Principal Medical Advisor t...

IntroductionMyriad Genetics, a renowned player in the field of genetic testing and precision medicine, has recently completed the acquisition of select assets from Intermountain Precision Genomics (IPG). The acquisition...

In a groundbreaking move that is set to revolutionize the field of genetic testing and precision medicine, Myriad Genetics, Inc. has announced its strategic acquisition of select assets from Intermountain Precision Geno...

In a groundbreaking move, Myriad Genetics, a leading molecular diagnostic company, has launched a comprehensive pan-cancer research platform aimed at revolutionizing patient care. With the Myriad Collaborative Research...